Pleiotropic effects of regular lipoprotein-apheresis

被引:11
|
作者
Sinzinger, Helmut [1 ]
Steiner, Sabine [2 ]
Derfler, Kurt [3 ]
机构
[1] Inst Diag & Treatment Lipid Disorders & Atheroscl, Vienna, Austria
[2] Univ Leipzig, Dept Intervent Angiol, Leipzig, Germany
[3] Med Univ Vienna, Dept Internal Med 3, Nephrol, Vienna, Austria
关键词
Endothelial function; Lipoprotein-apheresis; Pleiotropic effects; Microalbuminuria; Left ventricular ejection fraction; Homocysteine; ENDOTHELIAL PROGENITOR CELLS; SINGLE LDL APHERESIS; PLASMA-CONCENTRATIONS; DISEASE; HYPERCHOLESTEROLEMIA; MICROALBUMINURIA; VASOACTIVITY; PROGRESSION; SELECTIN; VCAM-1;
D O I
10.1016/j.atherosclerosissup.2017.05.032
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Lipoprotein(LP)-apheresis is the treatment of choice in patients suffering from severe familial hypercholesterolemia. A wide range of mechanisms has been claimed to be responsible for the known clinical benefit. Methods: Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of lipoproteins (DALI) or dextran sulfate (DS) were examined. A total volume of 10 l blood was exchanged. Non-lipid effects, mainly concerning endothelial function (circulating endothelial cells, circulating endothelial progenitor cells, flow-mediated vasodilation, microalbuminuria) as well as left ventricular ejection fraction and homocysteine were assessed. Results: A single LP-apheresis session improves paradox contractile response in statin intolerant patients, but not in those on regular statin therapy. In contrast, over a 6-months follow-up after treatment initiation, all the examined parameters (circulating endothelial cells, circulating endothelial progenitor cells, flow mediated vasodilatation, homocysteine, microalbuminuria and left ventricular ejection fraction) improved. When available, a comparison between DS vs. DALI was performed. In none of the subgroups a significant difference was noted. Discussion: These findings indicate that beyond the well known lipid/lipoprotein lowering action the broad spectrum of functional tests examined reflecting mainly endothelial function is significantly improved by LP-apheresis treatment on the long-term and seems to be a key underlying reason for the clinical improvement seen in these patients. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 127
页数:6
相关论文
共 50 条
  • [1] Beyond cholesterol-pleiotropic effects of lipoprotein apheresis
    Schettler, Volker J. J.
    Schettler, Elke
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 : 35 - 40
  • [2] Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment
    Derfler, Kurt
    Steiner, Sabine
    Sinzinger, Helmut
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (15-16) : 655 - 663
  • [3] Pleiotropic Effect of Lipoprotein-Apheresis on the Soluble Form of Activated Leukocyte Cell Adhesion Molecule (sALCAM) in Familial Hypercholesterolaemia
    von Bauer, Ruediger
    Oikonomou, Dimitrios
    Sulaj, Alba
    Kopf, Stefan
    Fleming, Thomas
    Rudofsky, Gottfried
    Nawroth, Peter
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2019, 127 (05) : 276 - 280
  • [4] Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment
    Kurt Derfler
    Sabine Steiner
    Helmut Sinzinger
    Wiener klinische Wochenschrift, 2015, 127 : 655 - 663
  • [5] Coronary plaque regression: Role of low density lipoprotein-apheresis
    Barter, PJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) : 228 - 230
  • [6] Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia
    Connolly, Katherine D.
    Willis, Gareth R.
    Datta, Dev B. N.
    Ellins, Elizabeth A.
    Ladell, Kristin
    Price, David A.
    Guschina, Irina A.
    Rees, D. Aled
    James, Philip E.
    JOURNAL OF LIPID RESEARCH, 2014, 55 (10) : 2064 - 2072
  • [7] Low-density lipoprotein-apheresis in two patients with extremely elevated lipoprotein (a) levels
    Bambauer, R
    Schiel, R
    Klinkmann, J
    JOURNAL OF CLINICAL APHERESIS, 1996, 11 (02) : 78 - 80
  • [8] Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia
    Gordon, BR
    Saal, SD
    CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (06) : 381 - 384
  • [9] Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia - The low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART)
    Matsuzaki, M
    Hiramori, K
    Imaizumi, T
    Kitabatake, A
    Hishida, H
    Nomura, M
    Fujii, T
    Sakuma, I
    Fukami, K
    Honda, T
    Ogawa, H
    Yamagishi, M
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (02) : 220 - 227
  • [10] Clinical trial of low density lipoprotein-apheresis for treatment of diabetic gangrene
    Iizuka, T
    Takeda, H
    Inoue, H
    Miyamoto, T
    Ito, H
    Omura, M
    Tsuji, H
    Chiba, S
    Nishikawa, T
    INTERNAL MEDICINE, 1997, 36 (12) : 898 - 902